Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04947137 · ClinicalTrials.gov registry record · Phase 2
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
A Phase 2 study, sponsored by Navidea Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT04947137 is a Phase 2 study that has completed, run by Navidea Biopharmaceuticals. The registered enrollment target is 134 participants.
The verdict
NCT04947137, a Phase 2 study, has completed, sponsored by Navidea Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.
Interventions
- DRUG Tc99m tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2022-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04947137
The ClinicalTrials.gov registry entry for NCT04947137 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc99m tilmanocept is the first listed.
NCT04947137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04947137 about?
NCT04947137 is a clinical study titled "Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept". This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.
What is the current status of trial NCT04947137?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2021-05-27. Estimated completion is 2022-01-21.
What interventions are being tested in trial NCT04947137?
The interventions under investigation include: Tc99m tilmanocept (DRUG).
Who is sponsoring clinical trial NCT04947137?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.